Malaysia set to produce its first human vaccine from 2028
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pharmaniaga will manufacture the PCV13 vaccine using technology transfer from a Chinese company, targeting production by 2028 — two years ahead of Malaysia's official 2030 capability goal.
- Chang Lih Kang, Malaysia's Science, Technology and Innovation Minister, said the COVID-19 pandemic exposed the country's vulnerability in depending on foreign suppliers who control vaccine delivery timing and pricing during crises.
- The PCV13 vaccine protects against 13 strains of Streptococcus pneumoniae bacteria, which cause pneumonia and meningitis.
- Malaysia currently imports 100% of its vaccines, sourced from the United States, France, Belgium, Japan, South Korea, India, Thailand and Indonesia.
- Malaysia is simultaneously developing a second vaccine — a hexavalent shot for children — as part of its push for technology sovereignty in critical health supplies.
Why it matters: Pharmaniaga becomes Malaysia's first domestic human vaccine producer, ending total import dependency across nine supplying nations and giving the government direct control over pricing and delivery timing during future health emergencies. The Chinese-sourced technology transfer also ties Malaysia's emerging vaccine supply chain to Beijing's biotech ecosystem.
